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BACKGROUND
Literature Review
Epithelial ovarian cancer, the most lethal of the gynecological cancers17, is typically
diagnosed at advanced stages19. Women diagnosed with advance-staged (i.e., stage III and IV
according to the International Federation of Gynecology and Obstetrics) epithelial ovarian
cancer are more likely to have recurrent episodes within 18 months17. According to a 20122016 case analysis conducted by the surveillance, epidemiology, and end results, or SEER
program, the incidence of ovarian cancer was 11.4 per 100,000 women in all races per year
with the highest incidence in non-Hispanic whites, of 11.9 per 100,000 women and the
lowest incidence in Asians / Pacific Islanders women, of 9.4 per 100,000 persons per year.
The mortality incidence was 7.0 per 100,000 persons in all races per year in the United
States43.
Many cancers originate from genetic mutations, including ovarian cancer26. Studies
indicate epithelial ovarian tumors develop in two distinctive pathways with type I arising
from ovarian epithelium and inclusion germ cell layers and type II deriving from fallopian
tubular epithelial origins. The mutation product of p53 results in various clinical symptoms
and end points20,33. Clinicians also have recognized the association of BRCA1 and BRCA2
genes with both of ovarian cancer and breast cancer2. A multivariate analysis conducted by
Gallagher et al.14 revealed that multiple organ systems are prone to be involved during an
ovarian malignancy, because there is a lack of distinct symptomatology, which allows the
cancer to spread prior to detection.

Numerous studies also have indicated assorted risk factors contribute to the incidence
and survival rate identifying racial/ethnical differences, genetic risk factors as the BRCA
genes, and nongenetic risk factors including reproductive and hormonal factors,
environmental and lifestyle factors. The racial differences in incidence and survival rates
within the United States resemble the global pattern, with the highest incidence and mortality
rates among non-Hispanic whites, followed by Hispanics, and the lowest incidence and
mortality rates are among non-Hispanic blacks and Asians25,43. The exact causes of racial
disparities of epithelial ovarian cancer is still left unclear, the reasons are likely to be
diverse5,21.
Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) both stimulate the
ovaries to produce steroids in females25. Simon et al (1983) concluded, based on in vitro
studies, that these hormones contribute to the malignant epithelial tumors. Aside from the
oral contraceptive use research conducted by CDC32, several hormonal factors also have been
associated with the development of epithelial ovarian cancer. Studies have suggested an
association between lower parity and an increased risk of developing aggressive epithelial
ovarian cancer6,23. Women with longer ovulatory history are exposed to a greater risk of
advanced epithelial ovarian cancer as well23. Women who have had a hysterectomy or
experienced early-age menopause are at reduced risk of epithelial ovarian cancer3. Menstrual
cycle irregularity and younger age at menarche also have been associated with lower risk of
deaths from high-grade epithelial ovarian cancer29.
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From 1990s to 2000s, there had been seven new hormonal contraceptive regimens
approved by the Federal Drug and Administration (FDA). The birth control shot, depot
medroxyprogesterone acetate (DMPA) along with the arm implant were introduced in the
1990s. The intrauterine device (IUD) that releases levonorgestrel daily was approved in
2000. The following year, transdermal patch and vaginal ring were brought to the market. In
2003, combined oral contraceptive were introduced to the public and became common and
popular7,39. All these various types of hormonal contraceptives differ in effectiveness and
availability, but they all introduce hormones to regulate ovulation and inhibit body’s natural
cyclic hormones to prevent pregnancy44.
Decades of research suggest that there are many factors related to the prognostic
characteristics of epithelial ovarian cancer; in fact, abundant sources have investigated the
association of hormonal factors to epithelial ovarian cancer. Thigpen et al (1993) analyzed a
pooled database from the Gynecologic Oncology Group and specified age as a determinant
for pathological outcome in which women aged 69 and older had a poorer prognosis than
younger women34. One of the early studies, conducted in the 1980s by the United States
Centers for Disease Control and Prevention (CDC), the Cancer and Steroid Hormone Study
(CASH), revealed that regular users of contraceptive pills for 10 years or more had a lower
lifetime risk of epithelial ovarian cancer38. Based on such findings, a World Health
Organization collaborative study further indicated that there were no remarkable differences
in the level of protection based on the levels of dosage in contraceptive pills27. Furthermore,
a meta-analysis conducted by Wheeler et al (2019) identified that any type of intrauterine
device they investigated was associated with a lower incidence of ovarian cancer36.
3

Public Health Significance
Ovarian cancer is the fifth leading cause of death from cancer among adult females
and the second most common gynecologic cancer in the United States42. Ovarian cancer
usually goes undetected until it has already developed into an advanced stage and has spread
to the pelvis and abdomen. The survival rate for ovarian cancer is generally as high as 92%
when detected in the early stage, however, due to the non-specific symptoms of ovarian
cancer and the lack of early detection tests, the 5-year survival rate for advanced stages can
be low as 30% in the United States40. Moreover, about 75% of patients are diagnosed at
advanced stages because of the asymptomatic nature of EOC19. EOC is the most predominant
pathological subtype accounting for more than 90% of all ovarian cancer33. According to the
global statistics report published by the World Ovarian Cancer Coalition in 2018, the risk of
ovarian cancer increases in more developed countries and urbanized areas, though the
survival rates in higher income countries vary by stage of diagnosis, awareness of the
disease, attitude and accessibility towards treatment41.
As noted, the development of EOC is associated with hormone-related risk factors,
disparity in the EOC development may be induced by various hormonal contraceptives13.
This study was designed to enhance our understanding of the hormonal factors associated
with the development of EOC by examining across various contraceptive methods.
Identifying unique and shared risk factors that contribute to increased risk for EOC will allow
public health professionals targeted programs to combat this deadly cancer.
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Descriptive Epidemiology
As stated above, multiple studies, including population-based studies have been
conducted that reveal an association between use of hormonal contraceptives and the
development of EOC. All studies considered for this review were screened using
predetermined inclusion and exclusion criteria. This systematic review analyzed all eligible
studies, examined the study measures used, and evaluated the validity and reliability of each
source.

Research Objectives
The overall goal of this study is to systematically analyze peer reviewed publications,
published between 2009 and 2019, that examined associations between hormonal risk factors
related to various types of contraceptive use and the subsequent development of epithelial
ovarian cancer.

Specific Aim
To identify potential hormonal risk factors induced by various hormonal
contraceptive use that influence the development of advanced stage II, III and stage IV
(FIGO) epithelial ovarian cancer.
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METHODS
Study Design
To meet the study objective and aim, I completed a systematic literature review. All
articles have been identified through a key word search (see Key Word Search next). The
purpose of this study is to methodically identify publications between 2009 and 2019, which
include analytical studies that examined advanced stage II, III and stage IV epithelial ovarian
cancer and use of hormonal contraceptives. The 10-year span for publications was set
considering the innovative emergence of hormonal contraceptive methods38. This systematic
review will analyze the differences in the development of ovarian cancer across various types
of hormonal contraceptive. Acquired data were secondary, sources were identified from
online academic databases, including using pre-determined inclusion and exclusion criteria.
All selected articles have been reviewed systematically. Articles that employed
nonrandomized samples and meta-analyses were analyzed using the Newcastle-Ottawa Scale
(NOS). The NOS has two assessment scales that have been designated for case-control
studies and cohort studies. The cross-sectional studies for this review were analyzed based on
the case-control studies considering the analytical parameters. The instruments used the
intraclass correlation coefficient (ICC)- and normative score to evaluate the extracted data for
internal reliability through Spearman rho to calculate the between-scale correlation10.

Key Word Search
Epithelial ovarian cancer, hormonal contraceptive, contraceptive skin patch, birth control
pill, vaginal ring, hormone-releasing contraceptive coils, hormone injection, hormonal birth
control implant, tubal ligation.
6

Study Subjects
1. Subjects: published peer-reviewed articles
2. Time: January 1, 2009 to December 31, 2019
3. Study design: systematic review

Eligibility Criteria
1. Inclusion
a. Study design: randomized controlled trials, cohort studies, case-control
studies, cross-sectional studies, and statistical analyses.
b. Research type: quantitative research
c. Study outcome measures: incidence rate, incidence rate ratio, percentage
attributable risk, hazards ratio, odds ratio, mortality risk
d. Risk factors: hormonal contraceptive methods including birth control pills,
contraceptive skin patch, vaginal ring, hormone-releasing contraceptive coils,
intrauterine device, arm implant, tubal ligation, and birth control injection.
2. Exclusion
a. Sources: non-English sources
b. Research type: qualitative research

Data Collection
Each database has been reviewed for journal titles, abstracts, and full-text articles to
avoid compromising sensitivity. All reference lists from the selected journal articles were
analyzed for potential inclusion of studies missed by the initial search. The selected studies
7

were screened for potential duplications of study populations in the Method section. In this
case, the study with higher level of evidence, greater number of patients, longer follow-up
period, or more thorough reporting of primary outcomes of interest would be used15. All the
eligible peer-reviewed publications were recorded in an accrual log to extract the valid
information suitable for the study objectives (See Accrual Log for Literature Review below).
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Accrual Log for Literature Review
Source

Database

Study Design

Study
Outcome
Measures

Study Setting
& Study
Population

Study
Intervention

Key
Findings

Quality
Assessment
Scale

Human Subjects Considerations
Due to the characteristic of systematic-review analysis, the human subject’s safety
considerations will not be applied to this study.

Completion Date 21-Aug-2018
Expiration Date 20-Aug-2021
Record ID
28257608

This is to certify that:

Cheng Cheng
Has completed the following CITI Program course:
Human Research
Group 2 Social and Behavioral Researchers and Key Personnel
1 - Basic Course

(Curriculum Group)
(Course Learner Group)
(Stage)

Under requirements set by:
University of Texas Health Science Center at Houston

Verify at www.citiprogram.org/verify/?wd1cb6453-54fb-48fc-ba27-e93734c8e64d-28257608

10

RESULTS
A total of 24 records were identified from the primary searches; ten full reports were
included in this review after full-text assessment3,8,9,11,13,16,18,31,35,37. Seven of the ten
comprised studies that investigated the association between oral
contraceptive3,8,9,11,13,18,31,35,37,, the most common form of hormonal contraceptive39, and the
development of epithelial ovarian cancer (Appendix A). The three other reports examined
tubal ligation31, depot medroxyprogesterone acetate (DMPA)37 and IUD16, and were grouped
for assessment in Appendix B.
Out of the seven studies investigating the association between oral contraceptive use
and the development of epithelial ovarian cancer (Appendix A), three yielded odds ratio, two
yielded hazards ratio, one relative ratio, and one investigated mortality risk and overall
survival time as measures of risk. For the studies that examined hormonal contraceptives
other than OC (Appendix B), two studies yielded odds ratio and one used hazards ratio as
measures of risk.

Quality Assessment
The ten selected studies had been divided into two groups based on the NOS scale for
the study characteristics – cohort studies and case-control studies. The quality assessment for
cohort studies have been recorded in Appendix C, and Appendix D concludes the quality
assessment for case-control studies and the derivatives.
As can be seen in Appendices C and D, the selected cohort studies in Appendix C are
of higher quality based on NOS assessment scale than the selected cross-sectional studies in
11

Appendix D. Only one out of the five selected cohort studies, published by Fortner et al
(2015), did quality for full-credit because it did not conclude statement regarding adequacy
of follow-up11. Three of the five selected cross-sectional studies (Appendix D) defined the
exposure using written self-reports8,11,31, which can potentially lead to information bias1.
Furthermore, three out of the five cross-sectional studies did not report or discuss the
non-response rate8,31,37; non-response bias can also impact the reliability for the included
studies29.

Study Characteristics
Seven out of the ten studies investigating the association between oral contraceptives
and advance-stage ovarian cancer are summarized in Appendix A. Appendix B summarizes
the other three forms of hormonal contraceptives. Five of the ten studies were cohort studies
(Appendix C), five were case-control studies or derivatives of case-control studies (Appendix
D). Three out of the seven studies examining the association between oral contraceptive use
and epithelial ovarian cancer analyzed odds ratio as the outcome measure8,9,11; two analyzed
hazards ratio as the outcome measure3,35; one measured mortality risks18; and one measured
relative risk12.
Five out of the seven studies reported in Appendix A concluded a protective effect
between oral contraceptive use and the development of ovarian cancer - three reported an
association between OC use and lowered risk in ovarian cancer development9,11,35; two
reported an association between OC use and improved cervical cancer survival outcomes13,18.
In contrast, two other studies included in Appendix A. Chen et al (2016) described an
12

association between OC users and higher frequency of ovarian cancer compared to non-OC
users8 and Besevic et al, (2015) reported an association between longer duration of OC use
and worse ovarian cancer survival3.
The studies investigating the association between other methods of hormonal
contraceptives and advance-stage ovarian cancer have been summarized in Appendix B. One
study, which investigated depot medroxyprogesterone acetate (DMPA), the birth control
shot37, reported a protective association between DMPA and EOC. Huang et al (2014)
examined intrauterine devices (IUDs) and tubal ligation; their study results revealed a
nonsignificant association between IUD use and ovarian cancer risk16 in contrast tubal
ligation was association with reduced ovarian cancer risk31. Two of the three studies were
based on case-control studies31,37 and the third study was cohort study16. Two out of the three
studies investigating other forms of contraceptives measured odds ratio, the other use
analyzed hazards ratio for the study outcome measure.
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DISCUSSION
Seven out of the ten articles summarized in the current report described a significant
reduction in risk of aggressive epithelial ovarian cancer development with the use of
hormonal contraceptives in the form of oral contraceptives, tubal ligation, Depot
medroxyprogesterone acetate (DMPA), Intrauterine Device (IUD). Specifically, a protective
association of ever use and longer duration of hormonal contraceptive and the development
of EOC was reported among these seven studies that concluded reduced risk. Two studies
reported a nonsignificant result, but the direction of these associations suggested a protective
association between contraceptive use and development of aggressive epithelial ovarian
cancer9,16. The study conducted by Besevic et al (2015), is the only study that reported a
harmful effect3.
Based on the European Prospective Investigation into Cancer initiative (EPIC), they
conclude that longer durations of OC use was associated with shorter survival time for
advanced-stage EOC patients (>10 years vs ⩽1 year of use: HR=1.74 95% CI=1.10–
2.75, Ptrend=0.01) 3. However, Tsilidis et al.35 and Fortner et al 13 also measured the
association between oral contraceptive use and the risk of ovarian cancer using the EPIC
data; both obtained conflicting results. Tsilidis et al concluded that women who used oral
contraceptive for 10 or more years had a significant 45% (HR, 0.55; 95% CI, 0.41–0.75)
lower risk compared with users of 1 year or less (P-trend, <0.01)35. Fortner et al obtained a
significant association between long duration of OC use and the risk of advanced-stage
EOC13. The discrepancy between the Besevic study and the latter two studies was the
identification of confounders in the process of statistical adjustment. Besevic et al controlled
14

for age, BMI, tumor stage, and smoking history; Tsilidis et al controlled for age, BMI,
menopausal status and parity; Fortner et al controlled for age, menopausal status, parity, and
menstrual cycle irregularity. The discrepancy of covariates may introduce a confounding bias
into the association, therefore, Besevic concluded an inverse association when all three
studies were derived from the same dataset.
All of selected studies suggested for a protective association between hormonal
contraceptives and the development of EOC controlled for, menopausal status, parity, and
age8,9,11,13,16,18,31,35,37, which have all been reported as potential confounders for birth control
use and epithelial ovarian cancer13. According to CDC (2019), women with higher
socioeconomic status tend to have better survival and less incidence due to access to
healthcare42. Furthermore, previous research has demonstrated that age, lower parity and
post-menopausal status has been associated with higher risk epithelial ovarian cancer28.
Out of the ten reported articles, four types of hormonal contraceptives were included,
many other common forms of birth control such as birth control implant and birth control
patch, have yet to be investigated with the association of EOC. Excluding OC, this study
identified only one article investigating the association between each form of hormonal
contraceptives and EOC.

Strengths and Limitations
As with most research, there are strengths and limitations of this review. One of the
strengths of this systematic review is the well-defined eligibility criteria for data acquisition.
The inclusion criteria for the publication year between 2009 and 2019 refined the relevancy
15

of the contraceptive methods that were assessed in the selected articles. Many of the
published articles were based on large dataset from cancer registries and analyzed validated
cases, which thereby eliminates information bias. Most of the reported studies did not
disclose their follow-up rates, which can potentially induce selection bias into the studies.
Four of the ten studies were conducted in Europe, and all analyzed OC use as the birth
control method based on the EPIC study. Three studies were conducted in Asia and the
remaining three were American studies based on data from cancer registries. This diversity of
racial/ethnic groups can also bias the results in a comprehensive comparison such as this. The
genomic variation between these racial/ethnical groups could also serve as a confounding
factor in these studies and bias the measure of association.
The investigated study samples ranged from hundreds to hundreds of thousands, these
large datasets can significantly impact the representative of the selected populations.
However, all the selected articles did not analyze the measure of association with the
considerations of potential confounders that would be contributed to the hormone levels of
patients, such as the discrepant oral contraceptive forms combined estrogen-progesterone,
progesterone only and the continuous or extended use pill12. As a final limitation for this
review, the selected articles analyzed three forms of hormonal contraceptive methods; thus,
the association between other hormonal contraceptives, the skin patch and vaginal ring for
instance, and ovarian cancer development, is yet to be known.
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Conclusion
Various hormonal contraceptives were analyzed for their association with the
development of ovarian cancer, and most revealed a protective effect among women. Future
studies should analyze the association based on the stratification of race/ethnics, genomic
variations, the specific form of oral contraceptive pills, and other topical hormonal
contraceptive methods.
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APPENDIX A

Source

Kolomeyevskaya, N. V. et al.
(2015). Oral Contraceptive Use
and Reproductive Characteristics
Affect Survival in Patients with
Epithelial Ovarian Cancer: A
Cohort Study. International
Journal of Gynecological Cancer.
25 (9): 1587-1592. DOI:
10.1097/IGC.0000000000000540
.

Database

Journals@Ovid
Complete

Cook, L. S. and Pestak, C. R. et
al. (2017). Combined Oral
Contraceptives Use Before the
First Birth and Epithelial Ovarian PubMed Central
Cancer Risk. Birtish Journal of
Cancer. 116: 265-269. DOI:
10.1038/bjc.2016.400.

Study Design

Study
Outcome
Measures

Study Setting & Study Population

Study Intervention

Key Findings

Overall survival time was calculated in months from the date of
diagnosis until the date of death or of last follow-up. Patients alive
at last contact were censored at the date of last contact. The
A history of OC use and parity are
Kaplan-Meier technique was used to compare survival across
associated with improved survival in
various exposures. Categorical exposures were tested using the logpatients diagnosed with ovarian cancer.
Women aged 18 to 99 years with
rank test, whereas continuous variables were analyzed with Cox
Overall
History of OC use was associated with a 35newly diagnosed EOC, fallopian regression. A threshold of P < 0.20 was used to identify candidate
survival
month improvement in median overall
Cohort Study
tube, or primary peritoneal
variables for final models. Final models were selected using a
time,
survival (81 vs 46 months; HR, 0.51; 95% CI,
carcinoma seeking care at
forward selection process; for consistency, covariates identified for
mortality risk
0.39–0.66), although this association was
Rosewell Park Cancer Institute.
any model were included in all adjusted models. Cox regression
attenuated when analyses were adjusted
was used to compute crude hazards ratios (HRs) and adjusted HRs
for age at diagnosis, stage, and histologic
(aHRs), as well as 95% confidence intervals (95% CIs). Linearity of
subtype (aHR, 0.71; 95% CI, 0.53–0.97).
associations between continuous variables and survival were
confirmed using linear spline models. The proportional hazards
assumption was verified for each factor of interest.

populationbased casecontrol study

odds ratio

Briefly, cases were identified from
the population-based BC and AB
cancer registries who were: age
20–79 years (40–79 in AB);
diagnosed with first primary,
incident, histologically confirmed
EOC (invasive EOC in AB); and able
Logistic regression to estimate adjusted odds ratios (aORs) and
to complete study in English. A
95% confidence intervals (CIs) in R software. Final aORs included
total of 1505 cases (60% of 2522
matching variables , age at FTTP, first degree family female breast
eligible) completed the study.
or ovarian cancer, tubal ligation, and BMI. Histotype-specific
Eligible controls identified from
analyses were restricted to high-grade serous and combined
provincial health rosters and a
endometrioid/clear cell.
mammography screening program
(Eheman et al, 2014) were: aged
20–79 years (40–79 in AB); able to
complete study in English; and, had
at least one ovary. A total of 2564
(53% of 4838 eligible) completed
the study.

Any COC use was associated with a
reduction in risk (aOR=0.58, 95% CI=0.49,
0.69). Among COC users, risk was most
strongly reduced with longer durations of
use overall, within more recent time since
last use, and for younger ages at first use.

Appendix A – Literature review of other forms of hormonal contraceptives

Quality
Assessment

9/9
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Source

Tsilidis, K. K. and Allen N. E et
al. (2011). Oral Contraceptive
Use and Reproductive Factors
and risk of ovarian cancer in the
European Perspective
Inesvtigation into Cancer and
Nutrition. British Journal of
Cancer. 105 (9): 1436-42. DOI:
10.1038/bjc.2011.371.

Database

PubMed Central

Study Design

Study
Outcome
Measures

Study Setting & Study Population

Participants recruited between
1992 and 2000 in 23 centers in 10
European countries (Denmark,
Hazard ratios (HRs) and 95% confidence intervals (CIs) were
France, Germany, Greece, Italy,
estimated using Cox proportional hazard models stratified by
The Netherlands, Norway, Spain,
centre and age, and adjusted for smoking status, body mass index,
Sweden and the United Kingdom)
unilateral ovariectomy, simple hysterectomy, menopausal
for the European Prospective
hormone therapy, and mutually adjusted for age at menarche, age
Cohort Study Hazards ratio
Investigation into Cancer and
at menopause, number of full-term pregnancies and duration of
Nutrition (EPIC). Incident cancer
oral contraceptive use. including linkage to health insurance
cases were identified through
records, cancer and pathology registries, and active follow-up of
linkage to population cancer
study participants or their next of kin in France, Germany and
registries in Denmark, Italy, The
Greece.
Netherlands, Norway, Spain,
Sweden and the UK, or using a
combination of methods.

The EPIC cohort was established
between 1992 and 2000 at 23
centers in 10 countries: Denmark,
France, Germany, Greece, Italy, the
Fortner, R. T. and Ose, J. et al.
Netherlands, Norway, Spain,
(2015). Reproductive and
Sweden and the United Kingdom.
hormone-related risk factors for
Participants were excluded if they
epithelial ovarian cancer by
reported history of prior cancer at
histologic pathways,
Wiley Online
Cohort study Relative risks
recruitment (except noninvasiveness and histologic
Library Database
melanoma skin cancer), had
subtypes: Results from the EPIC
incomplete baseline data, reported
cohort. International Journal of
bilateral oophorectomy at baseline,
Cancer. 137: 1196 - 1208. DOI:
or women missing data on all
10.1002/ijc.29471.
investigated reproductive and
hormone-related risk factors,
leaving a study population of
334,126 women.

Key Findings

Quality
Assessment

Women who used oral contraceptives for
10 or more years had a significant 45% (HR,
0.55; 95% CI, 0.41–0.75) lower risk
compared with users of 1 year or less (P trend, <0.01). Compared with nulliparous
women, parous women had a 29% (HR,
0.71; 95% CI, 0.59–0.87) lower risk, with an
8% reduction in risk for each additional
pregnancy. A high age at menopause was
associated with a higher risk of ovarian
cancer (>52 vs ⩽45 years: HR, 1.46; 95% CI,
1.06–1.99; P -trend, 0.02). Age at menarche,
age at first full-term pregnancy, incomplete
pregnancies and breastfeeding were not
associated with risk.
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Duration of OC use and number of full-term
pregnancies were inversely associated with
both type I and type II, but not borderline,
tumors (e.g., 10 years vs. never use of OC:
borderline, RR: 0.75. duration of OC use
was only signiﬁcantly associated with
reduced risk of serous tumors (e.g., OC use
10 years vs. never user, RR: 0.61
[0.46–0.82], ptrend < 0.01, phet 5 0.86)
[0.35– 1.61], ptrend 5 0.22; type I, RR: 0.54
[0.31–0.94], ptrend 5 0.01; type II, RR: 0.71
[0.51–0.97], ptrend 5 0.01; phet 5 0.22)..
Established protective factors, including
duration of oral contraceptive use and full
term pregnancy, were consistently inversely
associated with risk across histologic
subtypes (e.g., ever full-term pregnancy:
serous, RR: 0.73 [0.58–0.92]; mucinous, RR:
0.53 [0.30–0.95]; endometrioid, RR: 0.65
[0.40–1.06]; clear cell, RR: 0.34 [0.18–0.64];
phet 5 0.16).
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Study Intervention

Main exposure variables were categorized as follows: age at
menarche: 13, 14, 15 years; age at menopause: 48, 49–50,
51–54, 55 years; full-term pregnancy: yes/no; number of fullterm. All analyses were adjusted for OC use (ever/never), HRT use
(ever/never), age at menopause (continuous; pre-/perimenopausal
assigned median age at menopause), menopausal status at
baseline (pre- or perimenopausal/postmenopausal), and full-term
pregnancy (ever/never), except when the variable was the main
effect. pregnancies: 0, 1, 2, 31; breastfed: yes/ no; menstrual cycle
regularity: 26 days, 27–29 days, 301 days, none or irregular; OC
use: yes/no; OC duration: never user, 1 year, 1–4 years, 5–9 years,
10 years; hysterectomy: yes/no; HRT use: yes/no; BMI: normal
weight (<25 kg m22), overweight (25–30 kg m22), obese ( 30 mg
m22).
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Source

Chen, Y., Tan, X., Ding, Y., Mai,
B., Huang, X., Hu, G., & Luo, X.
(2016). WWOX CNV-67048
Functions as a Risk Factor for
Epithelial Ovarian Cancer in
Chinese Women by Negatively
Interacting with Oral
Contraceptive Use. BioMed
research international , 2016 ,
6594039.
doi:10.1155/2016/6594039

Clendenen, T. V. and Arslan, A.
A. et al. (2013). Circulating
prolactin levels and risk of
epithelial ovarian cancer. Cancer
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PubMed Central
epithelial ovarian cancer survival
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Study Design

case-control study

Nested case-control

cohort study

Study
Outcome
Measures

Study Setting & Study Population

Study Intervention

Key Findings

Quality
Assessment

odds ratio

549 EOC patients and 571 age (±5
years) matched cancer-free
controls were recruited from the
Guangdong Provincial Maternity
The chi-square test was used to assess differences in the
and Child Care Center in
distributions of CNV-67048 copy number between EOC cases and
significantly higher frequency of menarche
Guangzhou, China. Individuals with
controls. The unconditional logistic regression model with or
age less than 15 years, births number no
tumor history were excluded. Each without adjustment for surrounding factors including age, age at
less than 4, and reported null oral
participant was asked to denote menarche, number of births, menstrual history, oral contraceptive
contraceptive use were observed in EOC
3 mL peripheral blood sample and use, family history of cancer, smoking status, and alcohol intake
cases than in controls (P values are 0.039,
complete a questionnaire to collect
was used to infer odds ratio (OR) and 95% confidence interval
<0.001, and 0.039 in turn).
their data on sociodemographic,
(95% CI) for each association between the CNV-67048 and EOC
smoking status, alcohol
risk.
consumption, menstrual and
reproductive histories, and
contraceptive use.
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odds ratio

The participants were recruited
from the NYU Women’s Health
Study (NYUWHS), the Northern Cross-sectional analyses were preformed mutually adjusted for all
Sweden Health and Disease Study factors significantly associated with prolactin levels in our study Cases were less likely ot have used OCs (64
(NSHDS), and the ORDET cohort in
(age, parity, oral contraceptive use, and menopausal status).
vs. 70 %, p = 0.26). Past use of OCs was
Italy. In total, 230 ovarian cancer Multivariate conditional logistic regression models were adjusted
associated with lower prolactin levels in
cases and 432 controls (~2 per case for parity (ever/never had a full-term pregnancy) and use of oral
both pre- and post-menopausal women.
matched on age, menopausal
contraceptives (OCs, past/never).
status, and date of blood sampling)
were included.
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hazards ratio
from death
of EOC and
EOC-related
cause

Cases were identified through
linkage with national cancer
Hazard ratios (HRs) and 95% confidence intervals (CIs) were
registries in Denmark, Italy, The
calculated using Cox proportional hazards regression models.
Netherlands, Norway, Spain,
Among OC users a longer duration of use
Person-time was calculated as the number of days between EOC
Sweden and the UK. In France,
was associated with a worse survival (>10
diagnosis and the date of death, emigration, loss to follow-up or
Germany and Greece, cases were
years vs ⩽1 year of use: HR=1.74 95%
censoring, whichever occurred first. Multivariable models were
identified using insurance records,
CI=1.10–2.75, Ptrend =0.01). In a uniform
adjusted for covariates that were selected a priori because of their
cancer registries and active followsubgroup of FIGO stage II/III cases (all
known influence on risk of EOC death; age at diagnosis
up of participants. Data on tumour
histological subtypes), there was no
(continuous), BMI (<23 kg m−2, ⩾23–<25 (reference), ⩾25–<30,
invasiveness, histology, stage and
association between OC use or OC duration
⩾30), tumour stage (local (reference), regional, metastatic,
grade were available from cancer
of use with EOC-specific survival.
unknown) and smoking status (never (reference), former, current,
registries and a pathology record
unknown).
review. A total of 1025 women
diagnosed with EOC.
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APPENDIX B
Source

Sieh, W. and Salvador, S. et al. (2013). Tubal
ligation and risk of ovarian cancer subtypes: a
pooled analysis of case-control studies.
International journal of Epidemiology. 42(2):
578-89. DOI: 10.1093/ije/dyt042.

Wilailak, S. and Vipupinyo, C. et al. (2012).
Depot medroxyprogesterone acetate and
epithelial ovarian cancer: a multicentre
case–control study. BJOG. 119 (6):672–677.
DOI: 10.1111/j.1471-0528.2012.03298.x.

Huang, Z. and Gao, Y et al. (2014).
Contraceptive methods and ovarian cancer risk
among Chinese women: A report from the
Shanghai Women's Health Study. International
Journal of Cancer. 137 (3): 607-14. DOI:
10.1002/ijc.29412.

Database

Oxford University
Press Journals

Wiley Online
Library Database

Wiley Online
Library Database

Study Design

Pooled analysis
of case-control
studies

multicentre,
case–control
study.

populationbased,
prospective
cohort study

Study Outcome Measures

Odds ratio and 95%
confidence interval

Study Setting & Study Population

Study Intervention

Key Findings

Quality Assessment

Primary data from 13 population-based
case-control studies, Cases were women
newly diagnosed with invasive epithelial
ovarian cancer (N = 7942) or borderline
tumours (N = 2215). Eligible control
women had at least one intact ovary and
no history of ovarian cancer (N = 13 904).

Controls were matched to cases on geographical
region and age in all sites, and when warranted on
race/ethnicity. Odds ratios (ORs) and 95% confidence
intervals (CIs) were estimated using conditional
logistic regression matched on sets determined by
combinations of site, race/ethnicity (non-Hispanic
White, Hispanic White, Black, Asian, other) and 5-year
age categories, and adjusted for age as a continuous
variable, oral contraception use and number of fullterm pregnancies.

Tubal ligation was associated with a 29%
reduced risk of invasive ovarian cancer
overall (OR, 0.71; 95% CI, 0.66-0.77; P <
0.001), after accounting for study site, age,
race/ethnicity, oral contraceptive use and
number of full-term births.
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The use of DMPA was found to be associated
with a 39% reduction in the risk of EOC with
From 12 hospitals located across
an OR of 0.61 and a 95% CI of 0.44–0.85 (P =
Thailand, three hundred and thirty
0.002). A significant risk reduction (83%) was
The odds ratio (OR) and 95%
patients with EOC (‘cases’) and 982
Cases and controls were interviewed by trained
observed when the duration of DMPA use
confidence interval (95% CI)
matched controls were recruited from
interviewers using a standardised pre-tested
was >3 years (OR 0.17; 95% CI 0.07–0.39; P
were calculated to assess the
the 12 hospitals. Cases were newly
questionnaire. The factors associated with EOC were
< 0.001). Other factors associated with a
relationship between DMPA
diagnosed patients with EOC,
evaluated using univariate and multivariate analyses.
reduced risk of EOC were the use of
and EOC.
demonstrated pathologically. Controls
combined oral contraceptive pills and
were age-matched patients admitted to
breastfeeding. A factor associated with an
different wards in the same hospital.
increased risk of EOC was a family history of
gynaecological cancer.

Hazards ratio

at baseline from March 1997 to May
2000, adult Chinese women aged 40–70
years were recruited from seven urban
communities of Shanghai, China. .
Incident cancer cases were veriﬁed by
home visits and medical chart review.
Women who had a previous diagnosis of
any cancer, an unveriﬁed diagnosis of
cancer, a prior oophorectomy, unknown
menopausal status, those who died of
cancer without a speciﬁc cancer
diagnosis or were lost to follow-up were
excluded; a total of 70,259 women were
included in our analysis.

Cox proportional hazards regression was used to
derive hazard ratios (HRs) and 95% conﬁdence
Ever use of any contraception was associated
intervals (CIs) for associations between ovarian
with a nonsignificant reduction in ovarian
cancer risk and contraceptive methods. Contraceptive
cancer risk (HR: 0.86, 95% CI: 0.60–1.24).
methods evaluated in this study included IUD, OC, TL
Longer duration of IUD use was associated
and contraceptive shots; ever use was compared with
with lower ovarian cancer risk (p-value for
never use. Durations of exposure time were
trend 5 0.04). Compared with never users,
calculated as the interval between start and end of
women with durations of IUD use longer than
use, except for TL and IUD, where removal had not
the median (20 years) were 38% less likely to
occurred by baseline interview. All analyses were
develop ovarian cancer (HR: 0.62, 95% CI:
performed using SAS version 9.3 (SAS Institute, Cary,
0.40–0.97).
NC), and a two-sided probability with a signiﬁcance
level of 0.05 was used.
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APPENDIX C
Selection
Source

Representativeness of
the exposed cohort

Selection of the non
exposed cohort

Kolomeyevskaya, N. V. et al.
(2015). Oral Contraceptive Use
and Reproductive
Characteristics Affect Survival in
Somewhat
Patients with Epithelial Ovarian
represnetative of the
Cancer: A Cohort Study.
average ovarian cancer
International Journal of
cases in the community
Gynecological Cancer. 25 (9):
1587-1592. DOI:
10.1097/IGC.000000000000054
0.

drawn from the same
community as the
exposed cohort

Tsilidis, K. K. and Allen N. E et
al. (2011). Oral Contraceptive
Use and Reproductive Factors
and risk of ovarian cancer in the
European Perspective
Inesvtigation into Cancer and
Nutrition. British Journal of
Cancer. 105 (9): 1436-42. DOI:
10.1038/bjc.2011.371.

Drawn from the same
community as the
exposed cohort

Somewhat
represnetative of the
average ovarian cancer
cases in the community

Comparability
Ascertainment of
exposure

written self report

Written self report

Was follow-up long enough
for outcomes to occur

Adequacy of follow up of
cohorts

Overall
Score

Yes

Study cotrols for presence or absence of
specific medical comorbidities, as well
as reproductive factors including the use
of hormonal medications. Individual
subject information on treatment and
survival, tumor stage, grade, and
histologic type.

Record
linkage

Yes

Complete follow up
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Yes

Study controls for oral contraceptive use
as well as information on age at
menarche and menopause, numbers of
full-term pregancies, incomplete
pregnancies and age at first full-term
pregnancy.

Record
linkage

Yes

Subjects lost to follow up
unlikely to introduce bias,
>80% follow up
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Record
linkage

Yes

No statement

8/9

Record
linkage

Yes

Subjects lost to follow up
unlikely to introduce bias,
>80% follow up
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Fortner, R. T. and Ose, J. et al.
(2015). Reproductive and
hormone-related risk factors for
epithelial ovarian cancer by
Somewhat
histologic pathways,
represnetative of the
invasiveness and histologic
average ovarian cancer
subtypes: Results from the EPIC cases in the community
cohort. International Journal of
Cancer. 137: 1196 - 1208. DOI:
10.1002/ijc.29471.

Drawn from the same
community as the
exposed cohort

Written self report

Yes

Study controls for age at menarche, age
at menopause, parity and number of
full-term pregnancies, breast feeding,
menstrual cycle regularity, OC use and
duration, menopausal hormone
replacement therapy (MHT) use, and
hysterectomy

Bešević, J., Gunter, M. J.,
Fortner, R. T., Tsilidis, K. K.,
Weiderpass, E., Onland-Moret,
N. C., … Merritt, M. A. (2015).
Reproductive factors and
epithelial ovarian cancer
survival in the EPIC cohort
study. British journal of
cancer , 113 (11), 1622–1631.
doi:10.1038/bjc.2015.377

Drawn from the same
community as the
exposed cohort

Written self report

Yes

Study controls for reproductive history,
diet and lifestyle.

Somewhat
represnetative of the
average ovarian cancer
cases in the community

Outcome

Demonstration
that outcome of
Comparability of cohorts on the basis of Assessment
interest was not
design or analysis
of outcome
present t the
start of study
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Selection
Source

Huang, Z. and Gao, Y et al.
(2014). Contraceptive methods
and ovarian cancer risk among
Chinese women: A report from
the Shanghai Women's Health
Study. International Journal of
Cancer. 137 (3): 607-14. DOI:
10.1002/ijc.29412.

Representativeness of
the exposed cohort

Somewhat
represnetative of the
average ovarian cancer
cases in the community

Selection of the non
exposed cohort

Drawn from the same
community as the
exposed cohort

Comparability
Ascertainment of
exposure

Structured interviews

Outcome

Demonstration
that outcome of
Comparability of cohorts on the basis of Assessment
interest was not
design or analysis
of outcome
present t the
start of study

Yes

study controls for contraceptive use and
the duration of use, menopausal status,
age at recruitment, education, years of
ovulation, irregular ovulatory cycles
(yes/no), first-degree family history of
cancer (yes/no), body mass index (BMI),
regular physical activity within 5 years
(yes/no) and other contraceptive
methods (never/ever).

Record
linkage
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Was follow-up long enough
for outcomes to occur

Adequacy of follow up of
cohorts

Yes

Subjects lost to follow up
unlikely to introduce bias,
>80% follow up

Overall
Score
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APPENDIX D
Selection

Source

Is the case definition
adequate?

Representativeness of the cases

Selection of Definition
controls
of controls

Comparability
Comparability of cases and
controls the basis of the design
or analysis

Exposure
Overall
Score

Ascertainment of
exposure

Same method of ascrtainment for cases
and controls

Non-response rate

Written self report

Yes

Rate different and no
designation (60% for
cases and 53% for
controls)
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Yes, with independent
validation

Consecutive or obviously
representative series of cases

Community
controls

No history
of disease

Study controls for outcome
diagnosis date and reference
data as well as demographic,
lifestyle, and
medical/reproductive factors,
women provided information on
COC use, including dates or ages
of use

Chen, Y., Tan, X., Ding, Y., Mai, B.,
Huang, X., Hu, G., & Luo, X. (2016).
WWOX CNV-67048 Functions as a Risk
Factor for Epithelial Ovarian Cancer in
Chinese Women by Negatively
Interacting with Oral Contraceptive
Use. BioMed research
international , 2016 , 6594039.
doi:10.1155/2016/6594039

Yes, with independent
validation

Consecutive or obviously
representative series of cases

Community
controls

No history
of disease

Study controls for outcome and
information on
sociodemographic, smoking
status, alcohol consumption,
menstrual and reproductive
histories, and contraceptive use

Written self report

Yes

No designation

7/9

Clendenen, T. V. and Arslan, A. A. et al.
(2013). Circulating prolactin levels and
risk of epithelial ovarian cancer. Cancer
Causes & Control. 24:741-8. DOI:
10.1007/s10552-013-0156-6.

Yes, with independent
validation

consecutive or obviously
representative series of cases

Community
controls

No history
of disease

Study controls for age,
menopausal status, and date of
blood sampling

Structured interview
where blind to
case/control status

Yes

Non respondent
described

8/9

Yes, with independent
validation

Consecutive or obviously
representative series of cases

Community
controls

No history
of disease

Study controls for outcome and
geographical region and age in
all sites, and when warranted on
race/ethnicity

Written self report

Yes

No designation

7/9

Yes, with independent
validation

Consecutive or obviously
representative series of cases

Community
controls

Study controls for EOC diagnosis
and sociodemographic factors,
No history personal history, current disease,
of disease
family history, reproductive
history, contraceptive history and
use of female hormones

Structured interview
where blind to
case/control status

Yes

No designation

8/9

Cook, L. S. and Pestak, C. R. et al.
(2017). Combined Oral Contraceptives
Use Before the First Birth and
Epithelial Ovarian Cancer Risk. British
Journal of Cancer. 116: 265-269. DOI:
10.1038/bjc.2016.400.

Sieh, W. and Salvador, S. et al. (2013).
Tubal ligation and risk of ovarian
cancer subtypes: a pooled analysis of
case-control studies. International
journal of Epidemiology. 42(2): 578-89.
DOI: 10.1093/ije/dyt042.
Wilailak, S. and Vipupinyo, C. et al.
(2012). Depot medroxyprogesterone
acetate and epithelial ovarian cancer:
a multicentre case–control study.
BJOG. 119 (6):672–677. DOI:
10.1111/j.1471-0528.2012.03298.x.
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